China-based baby care products manufacturer Biostime International Holdings Inc. suffered a major loss in the stock markets following news the company is under investigation for possible anticompetitive conduct. According to reports, Biostime shares dropped up to 10 percent – its deepest drop in nearly two years – as the National Development and Reform Commission is looking into the firm for allegations of price-fixing. The case follows just months after Kweichow Moutai and Wuliangye Yibin were both fined by regulators for setting minimum retail prices, say reports.
Featured News
Judge Pushes Elite College Financial Aid Antitrust Trial Toward Thanksgiving Finish
Jul 23, 2026 by
CPI
Altria, Juul Ask Appeals Court to Reverse Antitrust Class Certification
Jul 23, 2026 by
CPI
Japan Expands Antitrust Watchdog’s Role With New Bureau for Big Tech Oversight
Jul 23, 2026 by
CPI
DOJ Introduces Faster Merger Review Process With Targeted Antitrust Requests
Jul 23, 2026 by
CPI
EU Hits Google With $1 Billion Fine in First Digital Markets Act Penalty
Jul 23, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes